Effect of cisplatin-based chemotherapy on emergence of cisplatin resistance, and its correlation with intracellular glutathione levels and accumulation of p53 protein in human ovarian cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 15, Issue 3, 2000, Pages 295-300

  Juvekar, A S ^a   Adwankar, M K ^a   Tongaonkar, H B ^b  

^a CANCER RESEARCH INSTITUTE   (India)

^b TATA MEMORIAL HOSPITAL   (India)

Author keywords

Chemosensitivity; Epirubicin; Glutathione cisplatin resistance; Ovarian cancer; P53

Indexed keywords

CISPLATIN; EPIRUBICIN; ETOPOSIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION FUNCTION; DRUG EFFECT; HUMAN; HUMAN CELL; OVARY CANCER; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0033853858     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497800414392     Document Type: Article

References (19)

1. Cotran RS, Kumar V, Robins SL. Pathologic basis of disease. 4th Ed. Philadelphia W.B. Saunders, 1989; 1158.
2. Hamilton TC, Young RC, Ozols RF. Experimental model systems of ovarian cancer: Applications to design and evaluation of new treatment approaches. Semin Oncol 1984; 11: 285.
3. Weisanthal LM, Lippman ME. Clonogenic and non clonogenic in vitro assays. Cancer Treat Rep 1985; 69: 615.
4. Godwin AK, Meister A, O'Dwyer PS, Haung CS, Hamilton TC, Anderson ME. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 89: 3070.
5. Mistry P, Kelland IR, Abel G, Sidhar S, Harrap KR. The relationship between glutathione, glutathione-S-transferase (GST) and cytotoxicity of platinum drugs and melphalanin eight ovarian cancer cell lines. Brit J Cancer 1991; 64: 215.
6. Britten RA, Geen JA, Warenius HM. Cellular glutathione (GSH) and glutathione-S-transferase (GST) activity in human tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys 1992; 24: 527.
7. Juvekar AS, Amonkar AJ, D'cruz AK, Saikia T, Pradban S. Chemosensitivity of advanced larynx carcinoma cells in vitro and significance of multidrug resistance markers in these tumors. Cancer Biother & Radiopharmaceuticals 1998; 13: 81-87.
8. Geran RJ, Greenberg NM, MacDonald MM, Schumacher AM, Abott BJ. Protocols for Screening chemical agents and natural products against animal tuomrs and other biological systems. Cancer Chemother Rep 1972; 3: 17.
9. Beutler E, Duron O, Kelly BM. Improved method for determination of blood glutathione. J Lab Clin Med 1963; 61: 882.
10. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr-1) gene expression in adult acute leukemias: Correlation with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586.
11. Chitnis M, Hegde U, Chavan S, Juvekar A, Advani S. Expression of the multidrug transporter P-glycoprotein and in vitro chemosensitivity: Correlation with in vitro response to chemotherapy in acute myeloid leukemia. Selective Cancer Therapeutics 1991; 4: 165.
12. Al-Azraqui A, Chapman C, Challen C et al. p53 alterations in ovarian cancer as a determinant of response to carboplatin. Br J Cancer 1994; 69: 7.
13. Brown R, Clugston C, Burns P, et al. Increased accumulation of p53 protein in cisplatin resistant ovarian cell lines. Int J Cancer 1993; 55: 678.
14. Pritsche M, Haessler C, Bradner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA damaging agents. Oncogens 1993; 8:307.
15. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 85: 1513.
16. Bosari S, Viale G, Radelli U, et al. P53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993; 24: 1175.
17. Hartman LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in the epithelial ovarian cancer. J Clin Oncol 1994; 12: 64.
18. Van der Zee, Hollema AG, Swurmeizer AJ, et al. The value of P-glycoprotein, glutathione-S-transferase c-erb B-2 and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995; 13: 70.
19. Vega FJ, Iniesta P, Caldes T, Sanchez A. et al. P53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. Br J Cancer 1997; 76: 44.